Biohaven reports Q2 EPS ($3.64), consensus ($1.77)

Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440M on June 30. CEO Vlad Coric commented, “Last quarter, we showcased an array of exciting updates across our pipeline spanning immunology, neuroscience, obesity, and oncology at our annual R&D Day…We are excited that we remain on timelines with multiple INDs from our MoDE platform for later this year, including drug candidates that target autoantibodies against beta-1AR for the potential treatment of dilated cardiomyopathy, galactose deficient IgA for IgA nephropathy and a further optimized IgG degrader for use in rare diseases.”